Sutro Biopharma is proud to sponsor Ovarian Cancer Research Alliance International Gynecologic Cancer Conference, featuring 25+ online sessions packed with research updates & more: bit.ly/GynCancerConf #SutroBio $STRO #GynCSM #GynecologicCancer #GynecologicalCancer #GynCancerConf
Sutro Biopharma, Inc.
Biotechnology Research
South San Francisco, California 11,096 followers
Changing the future of Oncology
About us
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
- Website
-
http://www.sutrobio.com
External link for Sutro Biopharma, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2003
Locations
-
Primary
111 Oyster Point Blvd
South San Francisco, California 94080, US
Employees at Sutro Biopharma, Inc.
Updates
-
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 at 1:30PM PT / 4:30PM ET. For more information, https://lnkd.in/gKtPGgN4 #SutroBio #ResearchForum #Webcast #ADC #BiotechNews $STRO
-
-
Sutro Biopharma to Participate in the Upcoming 2024 Wells Fargo Healthcare Conference, Thursday, Sept 5th at 3:00PM ET. Click the link to register and join the webcast, https://lnkd.in/gnkpaRkQ #SutroBio #Biotech #BiotechNews #WellsFargo $STRO
-
-
Congratulations to the Vaxcyte team on the impressive results from their Phase 1/2 VAX-31 vaccine (PCV) study! These results further validate our decade-long collaboration. Sutro is honored to have played a role by providing the essential extract used in the development of Vaxcyte’s cell-free vaccine candidates. Here’s to many more milestones together! Read the full press release here: https://lnkd.in/g72D5AUd
Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs. We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team. For more, read the full press release here: https://lnkd.in/g72D5AUd #Vaccines #Biotechnology #ProtectHumankind #PCV
-
-
🌟 September is Ovarian Cancer Awareness Month 🌟 Sutro is advancing ovarian cancer research with REFRαME-O1, investigational treatment that directly targets cancer cells with FRα. We’re dedicated to supporting women and their families while driving progress in treatment. 🔗 Learn more, https://lnkd.in/g2H9aKFH #OvarianCancerAwarenessMonth #SutroBio #CancerResearch #OvarianCancer #REFRαMEO1 $STRO
-
-
September is #ChildhoodCancerAwarenessMonth, a time to honor the strength and resilience of our young patients and their families. Sutro is dedicated to supporting these brave children and their journeys. Discover the inspiring stories of Project Stella’s children at https://lnkd.in/gKtRzDBN. Together, we’re making a difference. 🌟 @fredhutch #SutroBio #FightCancer #AML #PediatricCancer #PediatricAML $STRO
-
-
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer. For more info, https://lnkd.in/gZqBsYwX #Sutrobio #LungCancer #ClinicalTrials $STRO #BiotechNews #Luvelta #LungCancerAwareness #LungCancerSupport #LungCancerResearch
-
-
Hans-Peter Gerber, Chief Scientific Officer, will present at the Wedbush Securities PacGrow #Healthcare Conference on August 14, 2024 at 8:45AM ET. #Wedbush #SutroBio $STRO #Biotechnews
-
-
At Sutro, we believe in putting patients first, and that spirit extends to our team events as well. Our Summer Family Picnic was a perfect opportunity for our team and their families to come together, enjoy the sunshine, and celebrate our shared commitment to making a difference. #SummerFun #SutroPicnic #PatientsFirst #TeamBuilding #SutroBio $STRO
-
-
🎙️ ** Jane Chung, President & COO, in PharmaShots Spotlight!** We’re excited to share that Jane Chung was recently featured in a PharmaShots interview with Saurabh Chaubey. The discussion, titled “Expanding ADC Therapy: Jane Chung from Sutro Biopharma,” delves into the REFRaME-O1 clinical trial, which is set to expand the benefits of FRα-targeted therapies. This trial focuses on evaluating luvelta for women with platinum-resistant ovarian cancer. Discover Sutro Biopharma’s innovative approach and insights in the full interview! 🔗 https://lnkd.in/ge3UK-VE #SutroBio #PharmaShots #BiotechNews $STRO #FightingCancer #clinicaltrials